Requip PR
Sponsors
Rajesh Pahwa, MD, GlaxoSmithKline
Conditions
Parkinson Disease
Phase 3
Pramipexole Conversion to Ropinirole Controlled Release (CR)
CompletedNCT00275275
Start: 2006-01-31End: 2008-05-31Updated: 2012-08-24
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa
CompletedNCT01154166
Start: 2010-02-15End: 2011-09-29Updated: 2018-08-06
Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
CompletedNCT01536574
Start: 2010-09-02End: 2012-03-28Updated: 2018-08-13